Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer

Stem Cells and Development

Volumn 21, Issue 13, 2012, Pages 2355-2363

  Bao, Qi ^a,b   Zhao, Yue ^a   Niess, Hanno ^a   Conrad, Claudius ^c   Schwarz, Bettina ^a   Jauch, Karl Walter ^a   Huss, Ralf ^d   Nelson, Peter J ^e   Bruns, Christiane J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ZHEJIANG UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Apceth GmbH and Co KG   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BETA1 INTERFERON; BIOLOGICAL PRODUCT; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; GANCICLOVIR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PIGMENT EPITHELIUM DERIVED FACTOR; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SITIMAGENE CERADENOVEC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1;

ADIPOSE TISSUE; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; BIOSAFETY; BONE MARROW; BREAST CANCER; CANCER PATIENT; CANCER RESEARCH; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FIBROSARCOMA; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LEPTOMENINGEAL GLIOMA; LEWIS CARCINOMA; LIVER REGENERATION; MELANOMA; MENINGIOMA; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; TUMOR VOLUME; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; CELL DIFFERENTIATION; CELL ENGINEERING; CELL PROLIFERATION; GASTROINTESTINAL NEOPLASMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MESENCHYMAL STROMAL CELLS; TRANSGENES;

EID: 84865710501     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0060     Document Type: Review

References (86)

1. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317.
2. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
3. Huss R, M Heil, S Moosmann, T Ziegelhoeffer, S Sagebiel, C Seliger, et al. (2004). Improved arteriogenesis with simultaneous skeletal muscle repair in ischemic tissue by SCL (+) multipotent adult progenitor cell clones from peripheral blood. J Vasc Res 41:422-431.
4. Silva GV, S Litovsky, JA Assad, AL Sousa, BJ Martin, D Vela, et al. (2005). Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111:150-156.
5. Hodgkinson CP, JA Gomez, M Mirotsou and VJ Dzau. (2010). Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum Gene Ther 21:1513-1526.
6. Picinich SC, PJ Mishra, J Glod and D Banerjee. (2007). The therapeutic potential of mesenchymal stem cells. Cell-& tissue-based therapy. Expert Opin Biol Ther 7:965-973.
7. Kumar S, D Chanda and S Ponnazhagan. (2008). Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 15:711-715.
8. Liechty KW, TC MacKenzie, AF Shaaban, A Radu, AM Moseley, R Deans, et al. (2000). Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6: 1282-1286.
9. Horwitz EM, DJ Prockop, LA Fitzpatrick, WW Koo, PL Gordon, M Neel, et al. (1999). Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5:309-313.
10. Dvorak HF. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659.
11. Kucerova L, V Altanerova, M Matuskova, S Tyciakova and C Altaner. (2007). Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 67: 6304-6313.
12. Kidd S, E Spaeth, A Klopp, M Andreeff, B Hall and FC Marini. (2008). The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 10:657-667.
13. Coussens LM and Z Werb. (2002). Inflammation and cancer. Nature 420: 860-867.
14. Ren G, L Zhang, X Zhao, G Xu, Y Zhang, AI Roberts, et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2:141-150.
15. Ramasamy R, CK Tong, HF Seow, S Vidyadaran and F Dazzi. (2008). The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 251:131-136.
16. Plumas J, L Chaperot, MJ Richard, JP Molens, JC Bensa and MC Favrot. (2005). Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19:1597-1604.
17. Li H, Z Guo, X Jiang, H Zhu, Li X and N Mao. (2008). Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells 26:2531-2541.
18. Wei J, S Blum, M Unger, G Jarmy, M Lamparter, A Geishauser, et al. (2004). Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 5:477-488.
19. Spellman JE, SO Gollnick, PJ Zhang and TB Tomasi. (1996). Cytokine production by human soft tissue sarcomas: Implications for immunosuppression within the tumour bed. Surg Oncol 5:237-244.
20. Tada M, Y Sawamura, S Sakuma, K Suzuki, H Ohta, T Aida, et al. (1993). Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas. Cancer Immunol Immunother 36:251-259.
21. Buchwalder PA, T Buclin, I Trinchard, A Munafo, and J Biollaz. (2000). Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 20:857-866.
22. Ashkenazi A, RC Pai, S Fong, S Leung, DA Lawrence, SA Marsters, et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162.
23. Tsao AS, ES Kim and WK Hong. (2004). Chemoprevention of cancer. CA Cancer J Clin 54:150-180.
24. Einhorn S and D Grander. (1996). Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res 16:275-281.
25. Bocci V, F Carraro, A Naldini, E Borrelli, G Biagi, G Gotti, et al. (1990). Interferon levels in human pulmonary tumors are lower than plasma levels. J Biol Regul Homeost Agents 4:153-156.
26. Rainov NG. (2000). A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389-2401.
27. Studeny M, FC Marini, RE Champlin, C Zompetta, IJ Fidler and M Andreeff. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603-3608.
28. Studeny M, FC Marini, JL Dembinski, C Zompetta, M Cabreira-Hansen, BN Bekele, et al. (2004). Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:1593-1603.
29. Loebinger MR, A Eddaoudi, D Davies and SM Janes. (2009). Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 69:4134-4142.
30. Nakamizo A, F Marini, T Amano, A Khan, M Studeny, J Gumin, et al. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307-3318.
31. Hakkarainen T, M Sarkioja, P Lehenkari, S Miettinen, T Ylikomi, R Suuronen, et al. (2007). Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 18:627-641.
32. Grisendi G, R Bussolari, L Cafarelli, I Petak, V Rasini, E Veronesi, et al. (2010). Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 70:3718-3729.
33. Zolochevska O, G Yu, JM Gimble and ML Figueiredo. (2012). Pigment epithelial-derived factor and melanoma differentiation associated gene-7 cytokine gene therapies delivered by adipose-derived stromal/mesenchymal stem cells are effective in reducing prostate cancer cell growth. Stem Cells Dev 21:1112-1123.
34. Kim SM, JH Oh, SA Park, CH Ryu, JY Lim, DS Kim, et al. (2010). Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 28:2217-2228.
35. Eliopoulos N, M Francois, MN Boivin, D Martineau and J Galipeau. (2008). Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res 68:4810-4818.
36. Xin H, R Sun, M Kanehira, T Takahata, J Itoh, H Mizuguchi, et al. (2009). Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors. Mol Med 15: 321-327.
37. Gu C, S Li, T Tokuyama, N Yokota and H Namba. (2010). Therapeutic effect of genetically engineered mesenchymal stem cells in rat experimental leptomeningeal glioma model. Cancer Lett 291:256-262.
38. Hu M, JL Yang, H Teng, YQ Jia, R Wang, XW Zhang, et al. (2008). Anti-Angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model. BMC Cancer 8:306.
39. Uchibori R, T Okada, T Ito, M Urabe, H Mizukami, A Kume, et al. (2009). Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 11:373-381.
40. Miletic H, Y Fischer, S Litwak, T Giroglou, Y Waerzeggers, A Winkeler, et al. (2007). Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 15: 1373-1381.
41. Amano S, S Li, C Gu, Y Gao, S Koizumi, S Yamamoto, et al. (2009). Use of genetically engineered bone marrow-derived mesenchymal stem cells for glioma gene therapy. Int J Oncol 35:1265-1270.
42. Xiang J, J Tang, C Song, Z Yang, DG Hirst, QJ Zheng, et al. (2009). Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy 11:516-526.
43. Houghton J, C Stoicov, S Nomura, AB Rogers, J Carlson, H Li, et al. Gastric cancer originating from bone marrowderived cells. Science 306:1568-1571.
44. Tolar J, AJ Nauta, MJ Osborn, A Panoskaltsis Mortari, RT McElmurry, S Bell, et al. (2007). Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25:371-379.
45. Miura M, Y Miura, HM Padilla-Nash, AA Molinolo, B Fu, V Patel, et al. (2006). Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24:1095-1103.
46. Li H, X Fan, RC Kovi, Y Jo, B Moquin, R Konz, et al. (2007). Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: A model of agerelated tumorigenesis in mice. Cancer Res 67:10889-10898.
47. Qin Y, H Ji, Y Wu and H Liu. (2009). Chromosomal instability of murine adipose tissue-derived mesenchymal stem cells in long-Term culture and development of cloned embryos. Cloning Stem Cells 11:445-452.
48. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371:1579-1586.
49. McIntosh K, S Zvonic, S Garrett, JB Mitchell, ZE Floyd, L Hammill, et al. (2006). The immunogenicity of human adipose-derived cells: Temporal changes in vitro. Stem Cells 24:1246-1253.
50. Kyriakou CA, KL Yong, R Benjamin, A Pizzey, A Dogan, N Singh, et al. (2006). Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviralmediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. J Gene Med 8:253-264.
51. Sia KC, WK Chong, IA Ho, Y Yulyana, B Endaya, H Huynh, et al. (2010). Hybrid herpes simplex virus/Epstein-Barr virus amplicon viral vectors confer enhanced transgene expression in primary human tumors and human bone marrow-derived mesenchymal stem cells. J Gene Med 12:848-858.
52. Grabundzija I, M Irgang, L Mates, E Belay, J Matrai, A Gogol-Doring, et al. (2010). Comparative analysis of transposable element vector systems in human cells. Mol Ther 18:1200-1209.
53. Aronovich EL, RS McIvor and PB Hackett. (2011). The Sleeping Beauty transposon system: A non-viral vector for gene therapy. Hum Mol Genet 20(R1):R14-R20.
54. Von Luttichau I, M Notohamiprodjo, A Wechselberger, C Peters, A Henger, C Seliger, et al. (2005). Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 14:329-336.
55. Chamberlain G, H Smith, GE Rainger and J Middleton. (2011). Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: Effects of chemokines and shear. PLoS One 6:e25663.
56. Honczarenko M, Y Le, M Swierkowski, I Ghiran, AM Glodek and LE Silberstein. (2006). Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24:1030-1041.
57. Ponte AL, E Marais, N Gallay, A Langonne, B Delorme, O Herault, et al. (2007). The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. Stem Cells 25:1737-1745.
58. Ringe J, S Strassburg, K Neumann, M Endres, M Notter, GR Burmester, et al. (2007). Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 101:135-146.
59. Gao Y, A Yao, W Zhang, S Lu, Y Yu, L Deng, et al. (2010). Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene 29:2784-2794.
60. Beckermann BM, G Kallifatidis, A Groth, D Frommhold, A Apel, J Mattern, et al. (2008). VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99:622-631.
61. Knoop K, M Kolokythas, K Klutz, MJ Willhauck, N Wunderlich, D Draganovici, et al. (2011). Image-guided, tumor stroma-Targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol Ther 19:1704-1713.
62. Niess H, Q Bao, C Conrad, C Zischek, M Notohamiprodjo, F Schwab, et al. (2011). Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg 254:767-774; discussion 74-75.
63. Ram Z, KW Culver, EM Oshiro, JJ Viola, HL DeVroom, E Otto, et al. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354-1361.
64. Bang OY, JS Lee, PH Lee and G Lee. (2005). Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 57:874-882.
65. Lee PH, JW Kim, OY Bang, YH Ahn, IS Joo and K Huh. (2008). Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 83:723-730.
66. Kuo TH, T Kubota, M Watanabe, T Furukawa, S Kase, H Tanino, et al. (1992). Orthotopic reconstitution of human small-cell lung carcinoma after intravenous transplantation in SCID mice. Anticancer Res 12:1407-1410.
67. Zischek C, H Niess, I Ischenko, C Conrad, R Huss, KW Jauch, et al. (2009). Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 250:747-753.
68. Ra JC, IS Shin, SH Kim, SK Kang, BC Kang, HY Lee, et al. (2011). Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 20:1297-1308.
69. Sun CK, CL Chang, YC Lin, YH Kao, LT Chang, CH Yen, et al. (2012). Systemic administration of autologous adiposederived mesenchymal stem cells alleviates hepatic ischemiareperfusion injury in rats. Crit Care Med 40:1279-1290.
70. Aurich H, M Sgodda, P Kaltwasser, M Vetter, A Weise, T Liehr, et al. (2009). Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 58:570-581.
71. Ishikawa T, A Banas, K Hagiwara, H Iwaguro and T Ochiya. (2010). Stem cells for hepatic regeneration: The role of adipose tissue derived mesenchymal stem cells. Curr Stem Cell Res Ther 5:182-189.
72. Puglisi MA, N Saulnier, AC Piscaglia, P Tondi, S Agnes and A Gasbarrini. (2011). Adipose tissue-derived mesenchymal stem cells and hepatic differentiation: old concepts and future perspectives. Eur Rev Med Pharmacol Sci 15: 355-364.
73. Qiao L, Z Xu, T Zhao, Z Zhao, M Shi, RC Zhao, et al. (2008). Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 18:500-507.
74. Qiao L, TJ Zhao, FZ Wang, CL Shan, LH Ye and XD Zhang. (2008). NF-kappaB downregulation may be involved the depression of tumor cell proliferation mediated by human mesenchymal stem cells. Acta Pharmacol Sin 29:333-340.
75. Conrad C, Y Husemann, H Niess, I von Luettichau, R Huss, C Bauer, et al. (2011). Linking transgene expression of engineered mesenchymal stem cells and angiopoietin-1-induced differentiation to target cancer angiogenesis. Ann Surg 253:566-571.
76. Li GC, QH Ye, YH Xue, HJ Sun, HJ Zhou, N Ren, et al. (2010). Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci 101:2546-2553.
77. Li L, H Tian, W Yue, F Zhu, S Li and W Li. (2011). Human mesenchymal stem cells play a dual role on tumor cell growth in vitro and in vivo. J Cell Physiol. 226:1860-1867.
78. Qiao L, ZL Xu, TJ Zhao, LH Ye and XD Zhang. (2008). Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 269:67-77.
79. You MH, WJ Kim, W Shim, SR Lee, G Lee, S Choi, et al. (2009). Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model. J Gastroenterol Hepatol 24:1393-1400.
80. Wang SS, S Asfaha, T Okumura, KS Betz, S Muthupalani, AB Rogers, et al. (2009). Fibroblastic colony-forming unit bone marrow cells delay progression to gastric dysplasia in a helicobacter model of gastric tumorigenesis. Stem Cells 27:2301-2311.
81. Kidd S, L Caldwell, M Dietrich, I Samudio, EL Spaeth, K Watson, et al. (2010). Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12:615-625.
82. Shinagawa K, Y Kitadai, M Tanaka, T Sumida, M Kodama, Y Higashi, et al. (2010). Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 127:2323-2333.
83. Chen XC, R Wang, X Zhao, YQ Wei, M Hu, YS Wang, et al. (2006). Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis 27:2434-2441.
84. Wolf D, H Rumpold, R Koeck and E Gunsilius. (2005). Re: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 97:540-541; author reply 1-2.
85. Karnoub AE, AB Dash, AP Vo, A Sullivan, MW Brooks, GW Bell, et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancermetastasis. Nature 449:557-563.
86. Cousin B, E Ravet, S Poglio, F De Toni, M Bertuzzi, H Lulka, et al. (2009). Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PLoS One 4:e6278.